Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We got ourselves a freaking unicorn here.
The only caveat to all this is..
"AMPAkines (and GABAkines) are in a division we call EndeavourRx which is being considered for the possible establishment of another subsidiary".... Which this has been mentioned in filings for quite some time. Considering that all 3 platforms are at the point of human clinical trials, maybe there are more lucrative and sustainable paths where these assets belong?
It will be interesting going forward.
My understanding is that all filings need to be updated and then they can come off the EM to PINK and a more liquid trading especially for those traders crying to get back in now. But the response/vision bigtalan got was it won't be overnight and more a process maybe over days or weeks to get all filings updated. What would trading look like considering any company with human clinicals phase 2 in motion is valuable and one with likely 3+ human clinicals approaching within a year is extremely valuable compared to the OTC swamp.
.05 is only a 50 million valuation. How many other OTC companies have valuations in that range that dont even have any significant assets at all?
Yep, due diligence requires one to ask all kinds of questions, continually. Especially when an investment inexplicably stops communicating to stakeholders and investors the most basic up to date information that public companies must provide. In my opinion, this lack of communication/filings/website is just wasting precious time in establishing a communication strategy to the investment community and growing that awareness and investor base these assets deserve.
If someone did due diligence starting today and saw, hey they got a ampakine platform into a phase 2 department of defense funded clinical that would yield additional clinicals into ADHD, oh and by the way they have a gabakine candidate that has be successful in a dozen preclinicals, including robust NIH trials and superior to competitors in preclinicals and this will likely get NIH funded trials going early in 2025, oh and 1 more thing, they have an OSA program that has 20+ million valuation readied in Australia, probably waiting on S3 confirmation in USA, but promising nonetheless... If you only did due diligence on the assets all entering multiple human clinicals, one would be like wow this is probably a 50-100+ million company on the Nasdaq...
But nah, no website updates, no PR's about ANY recent activities, no SEC financial filings, etc... An outsider would be like :Huh, why? Those are most basic and easier building blocks of a publicly traded company; the science and acquiring government funding are much more difficult efforts!
China owned for sure. Don’t forget to mention that they are pink current.
No problem here so you must know everything as an investor sorry that a question upset you. Have a great weekend. Go back to IGPK and hope they pump it to make money off a website from China Owned goverment run companies you are waiting for a name change last I checked how long has it been 5 months now? just asking for a freind nah I an asking for me. Now go and have a great weekend ,when RSPI lands at .10 and from there out every .10 cent is a 1.5 million winfall , I will ask what questions I would like at this point. GLTA
Folks,
I also was in contact with Jeff Margolis and asked about CX929, Curious that his name was familiar .to me. Turns out I believe I met him at a Cortex annual meeting.
"I am not familiar with CX-929 and I have been with Cortex, now RespireRx for the last 11.5 years. I had also indicated that I would reach out to my scientific colleagues. This morning I spoke with our Chief Scientific Officer and he another colleague who happens to be familiar with some of the older colleagues, will get back to me. He was immediately familiar with CX-929, but did not know the details off the top of his head. We’ll dig in and get back to you." I am wondering if that paper was missed, and it is an overlooked jewel in the RSPI treasure chest?
We are good my little friend, it will open 0.0-0.05 on EM no worries.
U should sell when buyers buying ask .002! Damm I try help u man! Now u have to wait for awhile to get it back up....CEO won't budge on filing!
Yeah, I think their PR's highlight their 3 platforms and what the key assets are and what medical indications they believe are most applicable.
Its not like they have nothing to do. Update those filings, update that ancient website and whatever communication "strategy" exists, work with consultants, set up multiple human clinicals. Certainly all those who are stakeholders and have invested time, money and collaborative effort into this impressive pipeline would expect nothing less.
Meanwhile that Jeopardy tune is soothing... lol
0.002 , 20K
0.0004, 10K
Someone slap $40.
Leave them alone oh my gosh.
Nice Work Big T
Hopefully we get a follow up from J Margolis
I will speak with our scientific team and come back to you within a few days. I am not familiar with CX-929. I am familiar with CX-1739, CX-717 and CX-1942. I’ll need to dig in a bit.
Sincerely,
jeff
Jeff Eliot Margolis
Senior Vice President, Secretary, Treasurer, Chief Financial Officer & Member of the Board of Directors
RespireRx Pharmaceuticals Inc.
(direct) 917-834-7206
(email) jmargolis@respirerx.com
(eFax) 415-887-7814
I sent a question in , we will see if anything is given
Bigtalan: Can you find out why there has not been any published research by RSPI and./or associates with CX-929 since 2019? Was there an unexpected determination of detrimental effect in the long term that hasn't been published?
ORCA – Online Research
h t t p s://doi.org/10.10 1 6/j.ne u bior ev.2019.0 2.0 03
Enhancing Cognition through Pharmacological and Environmental Interventions: Examples from Preclinical Models of Neurodevelopmental Disorders
Lorenzo Morè1*, Julie C. Lauterborn2*, Francesco Papaleo3 and Riccardo Brambilla
“Recent work has begun to address the question of whether long-term ampakine treatment could be beneficial by assessing if this treatment regimen 24 offsets the deleterious effects of brain aging in hippocampus (Lauterborn et al., 2016). In these studies, 10-month old middle-aged rats were treated with the ampakine CX929 (5 mg/kg in 10% honey in water) or vehicle orally on a 5 day-on / 2 day-off schedule for three months and housed in an enriched environment during this period. The enriched housing bin was multi-tiered and contained a nest box, bedding, running wheel, chewable items, and novelty items that were changed weekly. Enrichment was given to both vehicle and ampakine treated animals to avoid possible negative effects of impoverished living associated with standard housing, and to test the effects of the compounds in a situation that is closer to what humans experience daily (i.e., environmental novelty and complexity, physical activity).
Effects of CX929 treatment on behavior were particularly striking, with the ampakine improving both long-term memory and self-organizing behavior. For these studies an unsupervised learning paradigm was used in which animals were allowed 30 min to freely explore a large arena that was divided into “rooms” containing unique objects and had an attached home box, and their forays beginning from the home box through arena space were analyzed; this task is self-directed, non reinforced. Middle-aged rats receiving ampakine or vehicle were initially tested in the apparatus beginning 5 weeks following the initiation of drug treatment to assess changes in their behavior, and then reassessed 4, 7, and 14 days later to evaluate long-term memory of the complex environment; testing was prior to the daily CX929 treatment to preclude circulating drug effects. For both groups of rats, the average numbers of forays in the apparatus were similar on the first day of testing. On subsequent test days the ampakine treated rats exhibited a marked reduction in total number of forays, whereas the vehicle group did not show this pattern and numbers of forays remained high even with the additional experience. A potential confound to these findings could be if the CX929 had affected arousal, but measures of distance travelled during explorations were not different between drug and vehicle treated groups suggesting little to no effect on arousal. Likewise, ampakine treated rats did not exhibit anxiety related behaviors such as preference for darken spaces or preference for being near walls as opposed to open spaces in the arena; both measures were equivalent between ampakine and vehicle treated groups. The results suggest that the change in exploration across days for the CX929 group reflected enhanced learning during the initial session that did not occur in the vehicle treated group. Next, it was evaluated whether there were differences in the movement patterns between the two groups of rats within the arena using a Markov sequence analysis; using this technique, predictions errors were calculated for an animal's location at different times in the future based on probabilities from its own past behavior for single transitions between sites within the arena (van der Heijden et al., 1990). These analyses revealed that the prediction errors for ampakine treated rats were significantly less than vehicle treated rats across the testing days, indicating that CX929 treatment helped to organize the exploratory behavior of the middle-aged rats into predictable patterns. Finally, consistent with the improvements in behavior, there were also marked improvements in hippocampal CA1 LTP and a restoration of neuronal cytoarchitecture, including increased dendritic branching and spine growth, in the CX929-treated rats.”
Well, I believe bigtalan got a reply from the company about their assets....
Their ampakine program is targeting SCI and then ADHD and possibly other orphan indications
KRM-ll-81 is a premier preclinical compound that can be gamechanger for epilepsy and pain
OSA program has potential and waiting on something to kick this off apparently
This is an absolute ton of potential baked into a little under resourced otc pharma trading on the EM. The otc sucks for these type of assets, but the otc does allow for those who seek to find and research undervalued gems hiding out a chance to accumulate a position dirt cheap. For me I think the snowball effect starts sooner than later here and the potential in these assets grow bigger and more dramatic over the next year. Glad to be able to invest, probably should just sit back with the popcorn and wait for the curtain to rise.
In my mind the RSPI's crown jewel is CX929.
Ask 485,200 - 0.002
Bid 1,000,000 - 0.0006
That's what I want , but Ill take a penny !
And that could be for starters...
How many biotechs and pharma OTC and Nasdaq companies trade for 100,200,400,500 million? Reason is if those potential gamechanger technologies breakthru they have huge market size and implications.
Respire has 3 platforms all progressing to human clinicals for medical indications that need better solutions. With much clinical and preclinical success in their back pocket, all of these platforms have the potential to be a gamechanger.
10 pennies would still only be 100 million valuation!! This phase 2 trial goes well and opens opportunity on the ampakine platform and/or they get their premier gabakine into phase 1 with grant funding are certainly pounding on the gamechanger door. Success in either could have this leaping by nickels...
They can flush me out for a penny lol !
It is a headscratcher as to the current EM status considering nearing the point of multiple human clinicals and leaving their investors starved for information.
It sure looks like somebody is trying to flush out shareholders
It is like that Jeopardy tune being stuck on replay.
At this point, everyone is invested or not. I guess one question is does the NIH take into account corporation financial stability when granting funds for human clinical trials? They surely did alot of complaining in past filings about the OTC status HINDERING their ability to finance and such, it would be sad if they chose to pause a regulatory filing process and it HINDERS acquiring grant funding or resources to move the pipeline forward..
Does ceo have plan to exit EM? Or a strategy to get shareholders to sell and leave?
Because it’s better than being left with shares that are literally worthless.
https://poland.us/strona,54,45965,0,fostering-collaboration-in-healthcare-dr.-nasiek-hosts-monthly-networking-event-with-industry-experts.html
Well it is October 1st, Q4 is here....
Hopefully this quarter is the beginning of a transformation for this pipeline, this company.
Looking forward to initiation of the big DOD funded phase 2 SCI clinical, which is a lead into to really expanding and exploiting the potential of the ampakine platform into ADHD and other medical indications.
They have stated they applied for grant funding for the epilepsy/pain candidate. Probably an early 2025 item on grant status based upon NIH online listed review process, but would love to hear some color as to how successful has KRM-ll-81 been in the NIH preclinicals. It cannot be understated how much potential this compound has, just read the preclinical success stories and hear the enthusiam in commentary. It holds significant unrealized value now, IMO.
The OSA program has been silent, yet they are attending a conference in November. I kinda wonder if the DEA schedule 3 status is the crux of the delay. With DEA hearing upcoming in December, it could be the catalyst to get that program in motion and extract the value.
It is disappointing that they chose to dig a hole in terms of PR/communications by pausing their filing status. It only makes sense if a much bigger financing and structure deal is in the works. That is logical since it is needed to carry on with 3 promising platforms, but also the actions of insiders and institutional clearly lining up behind equity positions is indicative. Updating and growing awareness and the shareholder base will be critical to realizing a high ROI for all stakeholders and for efficiently moving on these assets. Hopefully a new website and era of communication is fast approaching.
Looking forward to possibly an exciting quarter upcoming and really an even bigger 2025 as clinical trials get underway in possibily all 3 platforms. For me the due diligence has always pointed to mid major pharma assets/pipeline. Made the investment and now looking for these assets to flourish over the next year and beyond. Good Luck to us all.
I just needed a 24 pack of pbr. Chill dale
Everywhere red ! So don't feel bad! Terrible penny market start week and month
Well someone gave away shares for a $17 can of premium peanuts... Probably would get 100 cans worth down the road...
Just another day on the expert market. It doesn't mean anything other than making everyone's portfolio red. LOL
.0004 closed oh boy
I think the mere fact that they responded to shareholders questions and concerns and indicated a vision of how getting current will roll out suggests wheels are in motion. And they certainly need to be! They are prepping to soon begin a key DOD funded SCI phase 2 trial at a premier facility where both awareness and the potential to parlay swift and positive results into further actions/trials on the ampakine platform will be at an ALL TIME HIGH. Couple that with the consultant on the gabakine platform needing to search for partners and resources as prepatory to achieving NIH grant funding for a phase 1 trial and there is support funding needed in that regards too. Communication and presentation of the corporation will need to be much more than an otc swamp dweller to acquire the adequate partnerships, resources and support items to successfully roll out one of the most superior preclinical compounds into human epilepsy trials.
Time to awake little butterfly...
510K 0.002
610K 0.0004
Possible for CX929? "A Design Patent Application can be filed as a continuation, continuation-in-part or as a Division of another Design Patent Application or a Utility Application. Alternatively, a utility application can be filed as a continuation, continuation-in-part or as a Division of another Design Patent Application." I suspect the CX929 molecule was patented without specification as to utility, i.e., a nootropic.
0.0004 10K
0.002 10K
What’s bid and ask still the same?
I thought there was a way to extend patents. ????
Agree. Thats why I think they have boiled down the ampakine platform to the ones with the most potential moving forward. That is not to say the past efforts were not worthwhile, only that I think they can only choose so many paths with all the various ampakines developed over decade or two and they have chosen the ones most likely to lead to successful conclusions. It all does come together to tell a story and highlight why the current CX-1739 has the most promise to move forward.
I read in an old Cortex Pharmaceuticals SEC filing that the patent for CX929 was set to expire in Nov. 2022. You know more about all this stuff than me, but I was just wondering, if there is no longer any patent protection for RespireRx on the molecule? And if that was the case, how could RespireRx expect to benefit from positive developments on the research front related to that molecule?
Hard to say, could easily be many multiples more than that by then...
Imagine this phase 2 SCI trial is successful and then looks to partner with BP to get phase 3 established as well as ADHD and other potential trials going with this compound. That alone could get us there.
Also imagine their premier gabakine compound gets grant funding and enters highly anticipated epilepsy human clinicals. There could be major interest before those get started and certainly if any phase 1 is successful, this compound alone becomes a monster.
They clearly value their OSA program significantly, not sure what the hold-up is there, but assuming they resolve that and begin to get traction, that program is additive to valuation for sure.
It is easy to underestimate pharma story stocks. Any of the above platforms make a great story, having all 3 poised for clinical movement is outstanding.
People need to apply logic to their thoughts.
Does anyone believe that a company with these types of assets, approaching a DOD funded phase 2, likely to have grant funding a phase 1 next year, waiting on something to kick off OSA program, etc, etc... does anyone believe they could not have found "otc level" funding to keep current? Sure they could have but at what crappy deal rate? So they "paused" completing the filings and have indicated a continued focus on finding funding, and are they not at a stage of needing a more significant chunk and not a simple 100k otc level funding to support these key human clinicals and advancing the pipeline. I don't think anyone likes this EM, and even the company acknowledges "the look" of it all. No good excuse for letting these assets and their success getting to this point to wallow on this trading "market", However, they have chosen to mitigate dilution as much as possible, indicating they are positioned for that next step. The assets heading into multiple government funded clinicals surely are and deserve more in more ways than one. Now into Q4 and even moreso rolling into Q1 2025 and beyond, I believe this story it about to be told. Invest and listen or don't, that is everyone's choice.
That is not possibly true.
Everyone has a persuasion and unless an individual values their time at zero worth, all participating have "skin in the game"; directly or indirectly.
Followers
|
349
|
Posters
|
|
Posts (Today)
|
4
|
Posts (Total)
|
51854
|
Created
|
12/30/04
|
Type
|
Free
|
Moderators DTGoody crazy horse 0 Lime Time archilles jacksonjohn |
RespireRx Pharmaceuticals Inc. and its subsidiaries and business units are discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (“ADHD”), recovery from spinal cord injury (“SCI”), certain neurological orphan diseases and obstructive sleep apnea (“OSA”). The RespireRx Group is developing a pipeline of new and repurposed drug products based on our broad patent portfolios for two drug platforms: (i) neuromodulators, which include GABAkines and AMPAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or “PAMs”) GABAA receptors and AMPA-type glutamate receptors, respectively, and (ii) pharmaceutical cannabinoids, which include dronabinol, a synthetic compound that acts upon the nervous system’s endogenous cannabinoid receptors and
The RespireRx Group holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.
EndeavourRx: Neuromodulators
GABAkines. Under a License Agreement with the University of Wisconsin-Milwaukee Research Foundation, Inc. (“UWMRF”) and on behalf of its EndeavourRx business unit, RespireRx has licensed rights to certain selectively acting GABAkines because of their ability to selectively amplify inhibitory neurotransmission at a highly specific subset of GABAA receptors, thus producing a unique efficacy profile with reduced side effects. Preclinical studies have documented their efficacy in a broad array of animal models of interrelated neurological and psychiatric disorders including epilepsy, pain, anxiety, and depression in the absence of or with greatly reduced propensity to produce sedation, motor-impairment, tolerance, dependence and abuse. EndeavourRx currently is focusing on developing KRM-II-81 for the treatment of epilepsy and pain.
KRM-II-81 has displayed a high degree of anti-convulsant activity in a broad range of preclinical studies, including in treatment resistant and pharmaco-resistant models. Not only was KRM-II-81 highly effective in these models, but pharmaco-resistance or tolerance did not develop to its anti-convulsant properties. These latter results are particularly important because pharmaco-resistance occurs when medications that once controlled seizures lose efficacy as a result of chronic use and it is a principal reason some epileptic patients require brain surgery to control their seizures. In support of its potential clinical efficacy, translational studies have demonstrated the ability of KRM-II-81 to dramatically reduce epileptiform electrical activity when administered in situ to brain slices excised from treatment resistant epileptic patients undergoing surgery.
In addition, KRM-II-81 has displayed a high degree of analgesic activity in a broad range of preclinical studies. In intact animal models of pain, the analgesic efficacy of KRM-II-81 was comparable to or greater than commonly used analgesics. At the same time, KRM-II-81 did not display side effects such as sedation and motor impairment, but even more importantly, it did not produce tolerance, dependence, respiratory depression or behavioral changes indicative of abuse liability, which are produced by opioid narcotics and are at the heart of the opioid epidemic.
AMPAkines. Through an extensive translational research effort from the cellular level through Phase 2 clinical trials, RespireRx has developed a family of novel, low impact AMPAkines, including CX717, CX1739 and CX1942 that may have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and certain orphan indications. Our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials. Both compounds have also completed Phase 2 proof of concept trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression.
AMPAkines have demonstrated positive activity in animal models of ADHD, results that have been extended translationally into statistically significant improvement of symptoms observed in a Phase 2 human clinical trial of CX717 in adult patients with ADHD. Statistically significant therapeutic effects were observed within one week. We believe AMPAkines may represent a novel, non-stimulant treatment for ADHD with a more rapid onset of action than alternative non-stimulants, such as Straterra® (atomoxetine), and without the drawbacks of amphetamine-type stimulants.
In a series of important studies funded by grants from the National Institutes of Health and published in a number of peer reviewed articles, Dr. David Fuller (University of Florida), a long-time RespireRx collaborator, has demonstrated the ability of CX1739 and CX717, RespireRx’s lead AMPAkines, to improve motor nerve activity and muscle function in a number of animal models of spinal cord injury (SCI).
Form Type | Received | Period End Date | Report |
---|---|---|---|
8-K | 07/08/2024 | 07/02/2024 | PDFRTFHTMLXLS |
8-K | 05/29/2024 | 05/29/2024 | PDFRTFHTMLXLS |
8-K | 04/16/2024 | 04/10/2024 | PDFRTFHTMLXLS |
NT 10-K | 04/01/2024 | 12/31/2023 | PDFRTFHTMLXLS |
8-K | 02/02/2024 | 01/30/2024 | PDFRTFHTMLXLS |
8-K | 01/22/2024 | 01/18/2024 | PDFRTFHTMLXLS |
8-K | 12/11/2023 | 12/06/2023 | PDFRTFHTMLXLS |
10-Q | 11/17/2023 | 09/30/2023 | PDFRTFHTMLXLS |
NT 10-Q | 11/14/2023 | 09/30/2023 | PDFRTFHTML |
8-K | 10/12/2023 | 10/09/2023 | PDFRTFHTMLXLS |
DISCLAIMER:
Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions.
There is no express or implied solicitation to buy or sell securities.
The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned.
Readers are advised to conduct their own due diligence prior to considering buying or selling any stock.
All information should be considered for information purposes only.
No stock exchange has approved or disapproved of the information here
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |